Whole-Body MRI Versus PET in Assessment of Multiple Myeloma Disease Activity
Conor Shortt(Hospital of the University of Pennsylvania), Stephen Eustace(National Rehabilitation Hospital), John C. McHugh(Our Lady's Hospital), Karen Breen(Guy's and St Thomas' NHS Foundation Trust), Martin J. O’Connell(Duke University), Peter O’Gorman(University College Dublin), Tadhg G. Gleeson(Vancouver Hospital and Health Sciences Centre)
Cited by 184
Related Papers
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|383
Transcriptional regulator PRDM12 is essential for human pain perception
|Nature Genetics|2015|172
The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia
|British Journal of Haematology|2011|136
HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies
|Seminars in Thrombosis and Hemostasis|2017|125
Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom
|Thrombosis Research|2020|122